Literature DB >> 2507334

Mutant cells defective in poly(ADP-ribose) synthesis due to stable alterations in enzyme activity or substrate availability.

S Chatterjee1, N V Hirschler, S J Petzold, S J Berger, N A Berger.   

Abstract

We used two different approaches to develop cell lines deficient in poly(ADP-ribose) synthesis to help determine the role of this reaction in cellular functions. One approach to this problem was to develop cell lines deficient in enzyme activity; the other approach was to develop cell lines capable of growing with such low nicotinamide adenine dinucleotide (NAD) levels so as to effectively limit substrate availability for poly(ADP-ribose) synthesis. The selection strategy for obtaining cells deficient in activity of poly(ADP-ribose) polymerase was based on the ability of this enzyme to deplete cellular NAD in response to high levels of DNA damage. Using this approach, we first obtained cell lines having 37-82% enzyme activity compared to their parental cells. We now report the development and characterization of two cell lines which were obtained from cells having 37% enzyme activity by two additional rounds of further mutagenization and selection procedures. These new cell lines contain 5-11% enzyme activity compared to the parental V79 cells. In pursuit of the second strategy, to obtain cells which limit poly(ADP-ribose) synthesis by substrate restriction, we have now isolated spontaneous mutants from V79 cells which can grow stably in the absence of free nicotinamide or any of its analogs. These cell lines maintain NAD levels in the range of 1.5-3% of that found in their parental V79 cells grown in complete medium. The pathway of NAD biosynthesis in these NAD-deficient cells is not yet known. Further characterization of these lines showed that under conditions that restricted poly(ADP-ribose) synthesis, they all had prolonged doubling times and increased frequencies of sister chromatid exchanges.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507334     DOI: 10.1016/0014-4827(89)90358-3

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Growth-phase-dependent response to DNA damage in poly(ADP-ribose) polymerase deficient cell lines: basis for a new hypothesis describing the role of poly(ADP-ribose) polymerase in DNA replication and repair.

Authors:  S Chatterjee; N A Berger
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

2.  TFIIF, a basal eukaryotic transcription factor, is a substrate for poly(ADP-ribosyl)ation.

Authors:  J M Rawling; R Alvarez-Gonzalez
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

3.  Poly(ADP-ribose) polymerase: a guardian of the genome that facilitates DNA repair by protecting against DNA recombination.

Authors:  S Chatterjee; S J Berger; N A Berger
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

Review 4.  The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.

Authors:  S Mazurek; C B Boschek; E Eigenbrodt
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

5.  Depletion of the central metabolite NAD leads to oncosis-mediated cell death.

Authors:  Christopher Del Nagro; Yang Xiao; Linda Rangell; Mike Reichelt; Thomas O'Brien
Journal:  J Biol Chem       Date:  2014-10-29       Impact factor: 5.157

6.  Poly(ADP-ribose): historical perspective.

Authors:  T Sugimura; M Miwa
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

7.  3-aminobenzamide, a potent inhibitor of poly (ADP-ribose) polymerase, causes a rapid death of HL-60 cells cultured in serum-free medium.

Authors:  K Yoshihara; M Tsuyuki; A Itaya; Y Tanaka; T Kamiya
Journal:  Mol Cell Biochem       Date:  1994-06-29       Impact factor: 3.396

8.  Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.

Authors:  M Nagao; M Nakayasu; S Aonuma; H Shima; T Sugimura
Journal:  Environ Health Perspect       Date:  1991-06       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.